741P Clinical outcomes stratified by Charlson Comorbidity Index (CCI) score from a retrospective study of patients with advanced renal cell carcinoma (aRCC) who received cabozantinib as part of the UK Managed Access Program (MAP)

Authors :: Bhupinder Klair
Kate Fife
Agnieszka Michael
B. Venugopal
Bernadett Szabados
Valerie Perrot
Source :: Annals of Oncology. 31:S576-S577
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: medicine.medical_specialty
Cabozantinib
business.industry
Retrospective cohort study
Hematology
medicine.disease
chemistry.chemical_compound
Oncology
chemistry
Renal cell carcinoma
Charlson comorbidity index
Internal medicine
Medicine
business

Full Text Access

Tools